An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment.

Schey, S A; Cavenagh, J; Johnson, R; Child, J A; Oakervee, H; Jones, R W

Schey, S A; Cavenagh, J; Johnson, R; Child, J A; Oakervee, H; Jones, R W.

Affiliation

Schey SA; Department of Haematology, Guy's Hospital, King's College London Medical School, University of London, London SE1 9RT, UK. steve.schey@gstt.sthames.nhs.uk

Leuk Res ; 27(10): 909-14, 2003 Oct.

Article in En | MEDLINE | ID: mdl-12860011

Subject(s)

Multiple Myeloma/drug therapy; Thalidomide/administration & dosage; Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma/complications; Multiple Myeloma/mortality; Practice Guidelines as Topic; Remission Induction; Salvage Therapy; Survival Rate; Thalidomide/toxicity

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Thalidomide / Multiple Myeloma Type of study: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Leuk Res Year: 2003 Document type: Article

Search on Google

XML

PubMed Links